Developing Novel Therapeutics Based on Naturally Occurring Resistance Mechanisms

caVos Biotech leverages comparative genomics and AI to uncover novel mRNA therapeutics targeting longevity-related indications such as fibrosis, tissue regeneration and cancer. caVos is pioneering a multi-layer computational algorithm to unlock the genetic basis of extraordinary, naturally occurring “super traits” that underlie disease and age-fighting mechanisms perfected through evolution across multiple, independent animal species.

The caVos platform translates nature’s proven evolutionary defenses into first-in-class therapeutic candidates. By integrating comparative genomics with rigorous experimental validation, the company accelerates new target and drug discovery through systematically identifying and validating biologically effective, cross-species protein variants that have been conserved through evolution and drive superior cellular metabolism.